Aggressive lymphomas - New agents
Jeremy Abramson, M. Lia Palomba, Jon Arnason, Matthew Lunning, et al.
Conclusion: In the ongoing TRANSCEND NHL 001 study, liso-cel continues to demonstrate the ability to be safely delivered to patients with R/R B-cell NHL, including those with secondary CNS lymphoma, a population of patients with a highly unmet medical need. No excess NE was noted in this population. This cohort continues to be evaluated.
Giulia Perrone, Anna Guidetti, Anna Dodero, Paolo Corradini
Conclusion: Among all pts with r/r DLBCL only 24% presented clinical and disease characteristics suitable for CARTs treatment. Moreover, some eligible pts run the risk to become ineligible because of poor disease control. The 4 week period to obtain CART-cells is a major obstacle to successful treatment. CART-cell treatment needs to be planned earlier in the disease course to optimize the outcome. The feasibility in Italy over the last 6 months of CART cells treatment has been largely unsatisfactory and primarily limited by the lack of commercial products. Our observational study is ongoing.
Sung-Soo Yoon , Matthew Matasar, Laurie H. Sehn, Sarit Assouline, et al.
Conclusion: Step-fractionation has enabled continued dose escalation of mosunetuzumab with no apparent increases in toxicity, exhibiting a promising risk-benefit profile.
Thomas Witzig, Kami Maddocks, Sven de Vos, Roger Lyons, et al.
Conclusion: The combination of acalabrutinib plus pembrolizumab was well tolerated, with meaningful activity and some exceptional responders (>24 months) in these patients with relapsed/refractory diffuse large B-cell lymphoma. Randomized trials of the combination versus single agent are needed.
Ranjana Advani, Nancy Bartlett, Sonali Smith, Mark Roschewski, et al.v
Conclusion: 5F9+rituximab is a novel immunotherapy blocking a key macrophage/cancer checkpoint. It is well tolerated with rapid and durable responses observed in both heavily pre-treated DLBCL and indolent lymphoma patients. Ph2 enrollment is ongoing (NCT02953509). Funded by Forty Seven and the Leukemia and Lymphoma Society.
Rajat Bannerji, Jon Arnason, Ranjana Advani, Jennifer R. Brown, et al.
Conclusion: REGN1979 was well tolerated in pts with R/R B-NHL. No DLTs and no significant neurological toxicity were observed. Treatment with REGN1979 showed impressive efficacy with a 100% ORR in R/R FL starting at doses above 5mg. With increasing doses, more resistant tumors such as R/R DLBCL are showing benefit, approaching the ORR seen with R/R FL at 80 mg. Based on these efficacy findings, a phase 2 study testing a selected dose in R/R FL Gr 1-3a, R/R DLBCL, and other R/R B-NHL subtypes is planned.
Thomas Witzig, Lubomir Sokol, Won Seog Kim, Francine Foss, et al.
Conclusion: Preliminary activity of tipifarnib was observed in PTCL pts, particularly in those with tumors of AITL histology and high CXCL12 expression and enrollment in the CXCL12+ cohort continues.
Rong Tao, Lei Fan, Yongping Song, Yu Hu, et al.
Conclusion: Sintilimab is effective and well tolerated in r/r ENKTL and could be a promising treatment option for these patients. Early disease progression observed by PET scan in this study could be pseudo-progression as it did not correlate with poor outcome, which warrants further investigation. NCT03228836